Puncturing The ImClone Hype

Puncturing The ImClone Hype
Could ImClone Systems’ Erbitux be a powerful cancer fighter after all? Maybe.

A new study presented June 1 at a meeting of oncologists seems to boost that contention. But there are still reasons to doubt that Erbitux will be approved soon or that it will eventually be a blockbuster.

Comments are closed.

Do NOT follow this link or you will be banned from the site!
Get email updates

Get new actionable insights and updates from BiotechBlog